Human Platelet Lysate: GMP Buying Guide

Human platelet lysate (hPL) is a cell-culture supplement manufactured by lysing pooled or single-donor human platelet concentrates to release the growth factors stored in platelet alpha-granules — PDGF, TGF-β, VEGF, EGF, and IGF-1 among them. It is used in place of fetal bovine serum (FBS) to support the growth of human cells, most commonly mesenchymal stromal/stem cells (MSCs), in both research and clinical-grade cell-therapy manufacturing. For a lab manager or procurement officer, hPL sits at the intersection of two supply-chain problems: sourcing a human-origin biological raw material with donor traceability requirements, and qualifying that raw material for use in a process that may itself be regulated as part of a cell or gene therapy product.

This guide covers what hPL is and why it replaces FBS, what “GMP-grade” and “fibrinogen-depleted” actually mean when they appear on a certificate of analysis or vendor spec sheet, and the criteria a procurement or QA team should actually evaluate before selecting a supplier or lot.

Why hPL Replaces Fetal Bovine Serum

FBS has been the default serum supplement for mammalian cell culture for decades, but it carries several well-documented liabilities that matter more as a process moves from research bench to clinical manufacturing:

Xenogeneic exposure. FBS is an animal-derived product; culturing human cells intended for human administration in bovine serum introduces a xenogeneic component that regulators and accrediting bodies scrutinize, and that has been associated with immune sensitization in some clinical MSC studies.
Zoonotic and adventitious agent risk. FBS sourcing carries a documented risk profile around bovine spongiform encephalopathy (BSE) and other adventitious agents, which is why FBS lots require country-of-origin and BSE-risk documentation for regulated manufacturing.
Lot-to-lot variability and supply volatility. FBS composition varies significantly by lot, season, and geographic sourcing region, and global FBS supply has seen repeated price and availability volatility.
Ethical and animal-welfare concerns. FBS collection methods have drawn sustained criticism, adding a further motivation — alongside the regulatory and technical ones — for xeno-free alternatives.

hPL addresses the xenogeneic-exposure and zoonotic-risk concerns directly: it is a human-origin material, and platelet growth-factor content supports at least comparable, and in a number of published MSC-expansion comparisons superior, proliferation rates relative to FBS-supplemented media. It does not eliminate donor-sourcing risk — it replaces an animal-sourcing risk profile with a human-donor one, which is precisely why donor screening and traceability become the central procurement question (see below).

How hPL Is Manufactured

Commercial and blood-establishment-produced hPL is generally made from platelet concentrates collected for transfusion purposes — either units that have reached the end of their transfusion shelf life (platelets have a short dating period, typically five to seven days) and are redirected to lysate manufacture, or units collected specifically for that purpose. Manufacture typically involves:

Sourcing and donor screening. Platelet units are drawn from donors screened under the same infectious-disease testing regime that applies to blood donation for transfusion (e.g., HIV, hepatitis B and C, syphilis, and other transfusion-transmitted infection markers), and units are traceable to donor and collection records.
Pooling strategy. Lysate is produced either from a single donor or from a pool of multiple donor units. Pooling reduces donor-to-donor variability in growth-factor content but increases the number of donor exposures represented in a single lot; single-donor product does the reverse. This is a real, disclosed trade-off buyers should weigh against their process’s risk tolerance and regulatory pathway, not a settled “better” choice.
Lysis. Platelets are lysed, most commonly by repeated freeze-thaw cycling, to rupture the alpha-granule membranes and release growth factors into solution. Some manufacturers apply additional pathogen-reduction or pathogen-inactivation steps.
Clarification and, optionally, fibrinogen depletion. The lysate is centrifuged or filtered to remove cellular debris, then either supplied as-is or further processed to remove fibrinogen (see next section).
Release testing. Finished lots are typically tested for growth-factor content, endotoxin, sterility, and (depending on the manufacturer’s quality system) mycoplasma and adventitious agents before release with a certificate of analysis.

What “GMP-Grade” Human Platelet Lysate Actually Means

“GMP-grade” is not a single certification a product either has or lacks — it describes the quality system under which the material was manufactured, and buyers should verify what that specifically covers rather than accept the label at face value. For a raw material feeding into a regulated cell-therapy manufacturing process, the relevant questions are:

Is the hPL itself manufactured under a documented GMP or GMP-aligned quality system (e.g., ISO 13485 certification, a documented quality management system with change control, batch records, and CAPA), as distinct from being manufactured in a general research-reagent facility?
Is there a Drug Master File (DMF), or equivalent regulatory support file, on record with the relevant regulator that a cell-therapy sponsor can reference in an IND or marketing-authorization submission? Many GMP-grade hPL manufacturers maintain a Type II DMF with the FDA specifically so their customers can cite it as an ancillary-material support package, without the manufacturer disclosing proprietary process details directly to the customer.
Is donor and unit traceability documented and auditable, consistent with blood-establishment recordkeeping and, where applicable, ISBT 128 unit identification, since the platelet units are themselves sourced from blood-collection establishments?
Does the manufacturer support ancillary-material qualification along the lines described in USP General Chapter <1043>, “Ancillary Materials for Cell, Gene, and Tissue-Engineered Products,” which is the reference framework FDA reviewers commonly expect sponsors to use when qualifying raw materials like hPL that contact the cell product but are not part of the final formulation?

In practice, “research-grade” hPL and “GMP-grade” hPL are frequently produced by the same manufacturer from a comparable process, with the GMP-grade tier carrying additional documentation, tighter change control, and regulatory support files rather than a fundamentally different formulation. A procurement team evaluating a switch from research-grade to GMP-grade material for a clinical-track process should confirm the manufacturer can supply that documentation package, not just a higher price tier.

Fibrinogen-Depleted Human Platelet Lysate

Standard hPL retains plasma proteins carried over from the platelet concentrate, including fibrinogen. When hPL-supplemented media contacts residual calcium and coagulation factors, that fibrinogen can polymerize into fibrin, producing visible gel or clot formation in the culture vessel. This is a real operational problem, not a cosmetic one: fibrin clots can trap cells, interfere with media exchange and imaging, and complicate downstream processing.

The two established ways to manage this are:

Anticoagulation. Adding heparin to the culture medium prevents clot formation but introduces heparin as an additional additive, with its own lot-to-lot and sourcing considerations (heparin is itself an animal-derived product in most commercial forms), and has been reported to affect some differentiation assays (notably adipogenic differentiation in MSC protocols).
Fibrinogen depletion. The manufacturer removes fibrinogen from the lysate before sale — typically via a defibrination step during processing — producing a product that does not clot in culture without requiring heparin supplementation. This is the product typically marketed as “fibrinogen-depleted” or “defibrinated” hPL.

Fibrinogen-depleted hPL is generally the simpler choice for standardized, scalable manufacturing workflows, since it removes a process variable (heparin dosing) and a potential confound in differentiation studies. The trade-off is that defibrination is an additional processing step, and buyers should confirm what method the manufacturer uses and whether it materially changes growth-factor content or lot-to-lot consistency relative to the non-depleted product, since removing one plasma protein fraction is not guaranteed to leave every other component of the lysate unaffected. A specification sheet or certificate of analysis should state residual fibrinogen content directly rather than simply the label claim “fibrinogen-depleted,” and a buyer qualifying a new lot or supplier should request that data rather than assume it.

What to Evaluate Before Selecting an hPL Supplier or Lot

These are the dimensions a procurement or QA team can actually verify from vendor documentation, rather than relying on marketing claims:

Quality system tier — research-use-only vs. GMP-grade, and what specifically the manufacturer’s quality system covers (ISO 13485 certificate, DMF status, change-notification policy).
Donor sourcing and traceability — single-donor vs. pooled, screening panel applied to donors, and whether unit-level traceability records are available on request.
Fibrinogen status — standard vs. fibrinogen-depleted, with quantitative residual-fibrinogen data rather than a qualitative label.
Pathogen-reduction/inactivation steps applied during manufacture, if any, and what validation data supports them.
Release-testing panel — what each lot is actually tested for (growth-factor content, endotoxin, sterility, mycoplasma) and whether a certificate of analysis is issued per lot.
Lot-to-lot consistency data — growth-factor concentration ranges across recent lots, since this directly affects cell-expansion reproducibility.
Regulatory support package — availability of a DMF letter of authorization, or equivalent, that a cell-therapy sponsor can reference in a regulatory submission.
Supply continuity — single-donor sourcing can create tighter supply constraints than pooled sourcing; ask about typical lead time and backorder history, particularly for a process that needs to standardize on one lot or supplier for a defined manufacturing campaign.
Change-control notification — whether the supplier commits to notifying customers in advance of manufacturing-process changes that could affect an already-qualified raw material, which matters for any process that has locked hPL into a validated manufacturing procedure.

None of these criteria point to a single “best” commercial product or supplier — the right choice depends on whether the material is feeding a research protocol, a preclinical program, or a clinical-grade manufacturing process operating under an active IND, and each of those contexts has a different bar for documentation and traceability. Buyers can source GMP-grade platelet-derived materials either directly from a specialized hPL manufacturer or through a laboratory-supply distributor that carries that manufacturer’s catalog — the evaluation criteria above (quality system, traceability, and release testing) apply regardless of which channel supplies the material, and should be verified against the manufacturer’s own documentation rather than a distributor listing alone.

Frequently Asked Questions

Is human platelet lysate the same as platelet-rich plasma (PRP)?

No. PRP is a concentrated, largely intact platelet preparation typically used directly in clinical procedures (e.g., orthopedic or dermatologic applications) without lysis. hPL is manufactured specifically as a cell-culture supplement: the platelets are deliberately lysed to release their growth-factor content into solution, and the resulting product is used to supplement culture media rather than administered directly.

What is fibrinogen-depleted human platelet lysate used for?

It is used anywhere standard hPL would be used — most commonly MSC and other primary cell expansion for research or cell-therapy manufacturing — in workflows where avoiding fibrin clot formation without adding heparin is a priority, which is typically the case for scaled, standardized manufacturing processes and for differentiation assays where heparin could introduce a confound.

Does GMP-grade hPL guarantee regulatory acceptance of a cell-therapy process?

No single raw material’s grade guarantees anything about the finished product’s regulatory acceptance. GMP-grade hPL with supporting documentation (DMF reference, traceability records, release testing) gives a sponsor the raw-material qualification package that FDA reviewers expect to see referenced under a framework like USP <1043>, but the sponsor is still responsible for qualifying that specific material within its own process and manufacturing controls.

Can hPL be used for cell types other than mesenchymal stromal cells?

Yes. While MSC expansion is the most common and best-published use case, hPL and hPL-supplemented media formulations have also been used to support other primary human cell types, including fibroblasts and some endothelial and epithelial cell lines, though the specific growth-factor profile that makes hPL effective for MSCs is not automatically optimal for every cell type, and researchers should verify performance for their specific cell type before standardizing on it.

Human Platelet Lysate (hPL): GMP-Grade Sourcing and Fibrinogen Depletion Buying Guide

Ask about Human Platelet Lysate (hPL): GMP-Grade Sourcing and Fibrinogen Depletion Buying Guide